Analysis of the impact of naturally-acquired immunity on Shigella vaccine performance to inform clinical trials: A simulation-based modeling study
Analyse des Einflusses natürlich erworbener Immunität auf die Shigella-Impfstoffwirksamkeit zur Informierung klinischer Studien: simulationsbasierte Modellierungsstudie
PLOS Medicine · 21.10.2026 · 23 (10) · e1004878
DOI: 10.1371/journal.pmed.1004878 ↗Auf einen Blick
Simulationen zeigen: In Shigella-Studien kann die beobachtete Impfstoffwirksamkeit die tatsächliche Wirksamkeit unterschätzen. Das Ausmaß hing von Surveillance-Strategie und Annahmen zur Immunität ab.
Fragestellung
Wie beeinflusst natürlich erworbene Immunität die Schätzung der Shigella-Impfstoffwirksamkeit in klinischen Studien?
Methode
Simulation von Shigella-Impfstoffstudien in Niedrig-, Mittel- und Hochlast-Settings unter verschiedenen Annahmen zu Impf- und Infektionsimmunität.
Ergebnisse
Untersucht wurden 6 Studiendesigns. Nur aktive Surveillance für Infektion plus Single-outcome-Modelle war in allen Szenarien unverzerrt. Die anderen 5 Designs unterschätzten die VE um bis zu 20 % absolut.
Einschränkungen
Ergebnisse waren sensitiv gegenüber Eingangsparametern; diese beruhten auf Annahmen zur Shigella-Naturlgeschichte aus begrenzten publizierten Daten.
Schlussfolgerung der Autor:innen
Die beobachtete VE in Shigella-Impfstoffstudien unterschätzt wahrscheinlich die wahre VE; das Ausmaß hängt von den Modellannahmen ab. Sorgfältiges Studiendesign ist nötig.
Kernaussagen
- Nur aktive Surveillance für Infektion und Single-outcome-Modelle war unverzerrt.
- Andere 5 Designs unterschätzten die VE um bis zu 20 % absolut.
- Bias, 95 %-KI-Abdeckung und falsch-negative Rate waren bei hoher Last schlechter.
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift PLOS Medicine, online erschienen am 21.10.2026. Verfasst von Avnika B Amin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, Georgia, United States of America. Hauptthemen laut MEDLINE: Shigella Vaccines, Dysentery, Bacillary, Shigella, Vaccine Efficacy. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bill & Melinda Gates Foundation, NIAID NIH HHS, Bill and Melinda Gates Foundation.
Abstract (Originalsprache)
Background
Effective vaccines against Shigella , the leading bacterial cause of diarrheal disease globally, could prevent morbidity and mortality from shigellosis as well as limit antibiotic resistance. Several Shigella vaccine candidates are in late stages of development, and the design of large Phase 3 trials in target populations is underway. In high incidence settings, children are expected to rapidly accrue natural immunity such that after repeated pathogen exposure, unvaccinated infants may have similar levels of immunity as vaccinated infants. For this reason, in these settings estimates of vaccine efficacy (VE) may underestimate expected efficacy in a fully naïve population. To set expectations and support optimal planning of future Shigella vaccine trials, we aimed to quantify the potential impact of this phenomenon on VE estimates under different surveillance strategies and assumptions about Shigella immunity. Methods and findings We simulated Shigella vaccine trials in low-, medium-, and high-burden settings under different assumptions about vaccine- and infection-conferred immunity. We estimated VE against severe, Shigella -attributable disease and any Shigella -attributable diarrhea under six trial designs: active surveillance for Shigella infection or symptom-based reporting paired with single-outcome, stratified recurrent outcome, or crude recurrent-outcome Cox proportional hazards models. In each scenario, we evaluated bias, 95% confidence interval (CI) coverage, and the false negative rate. Only the trial design using active surveillance for infection and single outcome models was consistently unbiased across all examined scenarios. The other five designs underestimated VE by up to an absolute 20%, with a single outcome model paired with symptom-based reporting performing least poorly. Bias generally was worse at higher-burden sites. For realistically sized trials, the 95% CI coverage and false negative rate were also worse at higher-burden sites. The results were sensitive to input parameters which depended on assumptions about Shigella natural history based on limited published data.
Conclusions
The observed VE in Shigella vaccine trials is likely to underestimate true VE, though the magnitude of underestimation described here is conditional on the simulation’s inputs and assumptions. Careful trial design is needed to minimize this underestimation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, Georgia, United States of America.
- Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, United States of America.
- Division of Infectious Diseases & International Health, University of Virginia, Charlottesville, Virginia, United States of America.
ORCID-Profile: Avnika B Amin, Maria Garcia Quesada, Daniel Trudell, Natalie E Dean, Benjamin A Lopman, James A Platts-Mills, Elizabeth T Rogawski McQuade
Förderung
- Bill & Melinda Gates Foundation
- NIAID NIH HHS
- Bill and Melinda Gates Foundation
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Amin, A. B., Garcia Quesada, M., Trudell, D., Dean, N. E., Lopman, B. A., Platts-Mills, J. A., & Rogawski McQuade, E. T. (2026). Analysis of the impact of naturally-acquired immunity on Shigella vaccine performance to inform clinical trials: A simulation-based modeling study. PLOS Medicine, 23(10), e1004878. https://doi.org/10.1371/journal.pmed.1004878
Vancouver
Amin AB, Garcia Quesada M, Trudell D, Dean NE, Lopman BA, Platts-Mills JA, et al. Analysis of the impact of naturally-acquired immunity on Shigella vaccine performance to inform clinical trials: A simulation-based modeling study. PLOS Medicine. 2026;23(10):e1004878. doi:10.1371/journal.pmed.1004878
BibTeX
@article{Amin2026,
author = {Amin, Avnika B and Garcia Quesada, Maria and Trudell, Daniel and Dean, Natalie E and Lopman, Benjamin A and Platts-Mills, James A and Rogawski McQuade, Elizabeth T},
title = {Analysis of the impact of naturally-acquired immunity on Shigella vaccine performance to inform clinical trials: A simulation-based modeling study},
journal = {PLOS Medicine},
year = {2026},
volume = {23},
number = {10},
pages = {e1004878},
doi = {10.1371/journal.pmed.1004878}
}
EUVIMED